Avatrombopag tablets ( DrugBank: Avatrombopag )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	2

63. 特発性血小板減少性紫斑病

---

臨床試験数 : 363 /  薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00625443 (ClinicalTrials.gov)	May 2007	19/2/2008	Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003	A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003	Idiopathic Thrombocytopenic Purpura	Drug: Blinded (placebo);Drug: Open Label (Avatrombopag tablets);Drug: Blinded (Avatrombopoag tablets)	Eisai Inc.	NULL	Completed	18 Years	N/A	All	53	Phase 2	United States
2	NCT00441090 (ClinicalTrials.gov)	February 2007	27/2/2007	Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)	A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).	Chronic Idiopathic Thrombocytopenic Purpura;Purpura, Thrombocytopenic, Idiopathic	Drug: Placebo;Drug: Avatrombopag tablets	Eisai Inc.	NULL	Completed	18 Years	N/A	All	64	Phase 2	United States